SBF2-AS1

Across TCGA pan-cancer cohorts, SBF2-AS1 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated SBF2-AS1 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SBF2-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SBF2-AS1 expression acts as an unfavorable survival marker, although some lineages such as CESC and KIRC show a favorable association.

LIHC, CESC, and KIRC are the cancer types where SBF2-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.437	0.640	<.001	88	view →
CESC	OS	Tertile	III,IV	0.863	0.464	.002	62	view →
KIRC	OS	Median	All	0.721	0.541	<.001	50	view →
LGG	OS	Median	All	0.719	0.887	<.001	49	view →
UVM	DFS	Tertile	All	0.321	0.842	<.001	43	view →
ACC	DFS	Tertile	All	0.549	0.857	.002	41	view →
READ	DFS	Median	All	0.880	0.745	.003	33	view →
GBM	OS	Tertile	All	0.236	0.469	.007	30	view →
SKCM	DFS	Tertile	All	0.236	0.134	<.001	29	view →
STAD	DFS	Quartile	All	0.608	0.857	.004	24	view →
KIRP	DFS	Median	IV	0.037	0.527	.004	24	view →
ESCA	DFS	Quartile	III,IV	0.302	0.650	.004	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

SBF2-AS1–LIHC (DFS)

Open the LIHC breakdown →